不同喂养配方改善极低出生体质量儿喂养不耐受的临床效果

来源期刊：广州医药 | 69-72 发布时间：2022-08-03 收稿时间：2025/11/13 18:20:09 阅读量：21

作者：: 黎小兰,

宋燕燕,

周伟,

蔡岳鞠,

关键词：: 母乳喂养深度水解奶极低出生体质量儿喂养失败喂养不耐受; breast feeding extensively hydrolyzed formula very low birth weight infants feeding failure feeding intolerance

DOI：: 10.3969/j.issn.1000-8535.2022.04.016

收稿时间：: 2021-07-27
修订日期：
接收日期：
引用总数：: 3

目的探讨在早期早产儿配方奶(PF)喂养失败下,更换母乳(HM)或深度水解奶(eHF)对极低出生体质量儿喂养不耐受(FI)的改善情况。方法选择2016年1月—2018年1月在广州市妇女儿童医疗中心出生、生后PF喂养失败、出现FI的极低出生体质量儿84例,根据家长HM喂养意愿及条件,分为HM喂养组38例和eHF喂养组46例,比较2组患儿更换喂养配方后FI消失时间、FI改善率、达全肠内喂养时间及体质量增长情况等喂养结局。结果相对于eHF喂养组,HM喂养组FI消失时间更快,FI改善率更高,达全肠内喂养时间更快,差异有统计学意义。HM喂养组平均每日体质量增长量、出院时体质量均明显大于eHF喂养组,住院时间更短,出院时宫外发育迟缓(EUGR)发生率更低,差异有统计学意义。2组患儿坏死性小肠结肠炎、胆汁淤积症、院内感染发生率比较无统计学差异。结论当极低出生体质量儿PF喂养失败、出现FI时,选择HM或eHF均可改善FI,但HM效果更好,达全肠内喂养时间更快且体质量增长更理想,出院时EUGR发生率较低。

1、 SPIEGLER J, PREU? M, GEBAUER C, et al. Does breastmilk influence the development of bronchopulmonary dysplasia?[J]. J Pediatr,2015(169):76-80.

2、 BASUKI F, HADIATI D R, TURNER T, et al. Dilute versus fullstrength formula in exclusively formula-fed preterm or low birth weight infants[J]. Cochrane Database Syst Rev, 2019,(6): CD007263.

3、 BROWN J V, EMBLETON N D, HARDING J E, et al. Multi-nutrient fortification of human milk for preterm infans[J]. Cochrane Database Syst Rev, 2016(5):CD000343.

4、 ASSAD M, ELLIOTT M J, ABRAHAM J H. Decreased cost and improved feeding tolerance in VLBW infants fed an exclusive human milk diet[J]. J Perinatol, 2016,36(3):216-220.

5、 DUTTA S, SINGH B, CHESSELL L, et al. Guidelines for feeding very low birth weight infants[J]. Nutrients, 2015, 7(1): 423-442.

6、 FLEISCHER D M, VENTER C, VANDENPLAS Y. Hydrolyzed formula for every infant?[J]. Nestle Nutr Inst Workshop Ser, 2016(86):51-65.

7、 FORD S L, LOHMANN P, PREIDIS G A, et al. Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk[J]. Am J Clin Nutr, 2019, 109(4): 1088-1097.

8、余章斌,韩树萍,陈玉林,等.我国早产儿喂养不耐受危险因素的Meta分析[J]. 中国新生儿科杂志,2010,25(6):346-350.

9、胡晓艳,常艳美,李在玲.早产儿喂养不耐受的临床特征及危险因素[J]. 中华围产医学杂志, 2020,23(3):182-187.

10、 CLARK R H, THOMAS P, PEABODY J. Extrauterine growth restriction remains a serious problem in prematurely born neonates[J]. Pediatrics, 2003, 111(5): 986-990.

11、 BELL M J, TERNBERG J L, FEIGIN R D, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging[J]. Ann Surg,1978,187(1):1-7.

12、中华医学会肠外肠内营养学分会儿科协作组;中华医学会儿科学分会新生儿学组;中华医学会小儿外科学分会新生儿学组.中国新生儿营养支持临床应用指南[J]. 临床儿科杂志,31(12):1177-1182.

13、 NG D H C, KLASSEN J, EMBLETON N D, et al. Protein hydrolysate versus standard formula for preterm infants[J]. Cochrane Database Syst Rev, 2017,10(2):CD012412.

14、 CORVAGLIA L, MARIANI E, ACETI A, et al. Extensively hydrolyzed protein formula reduces acid gastro-esophageal reflux in symptomatic preterm infants[J]. Early Hum Dev, 2013,89(7):453-455.

15、 HAY W W, HENDRICKSON K C. Preterm formula use in the preterm very low birth weight infant[J]. Semin Fetal Neonatal Med, 2017,22(1):15-22.

16、 QUIGLEY M, EMBLETON N D, MCGUIRE W. Formula versus donor breast milk for feeding preterm or low birth weight infants[J]. Cochrane Database Syst Rev, 2018,6:CD002971.

17、 SULLIVAN S, SCHANLER R J, KIM J H, et al. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products[J]. J Pediatr, 2010, 156(4): 562-567.

18、 ASSAD M, ELLIOTT M J, ABRAHAM J H. Decreased cost and improved feeding tolerance in VLBW infants fed an exclusive human milk diet[J]. J Perinatol, 2016, 36(3): 216-220.

19、 American Academy of Pediatrics. Breastfeeding and the use of human milk[J]. Pediatrics, 2012, 129(3): e827-e841.

20、中国医师协会新生儿科医师分会循证专业委员会. 早产儿喂养不耐受临床诊疗指南(2020) [J]. 中国当代儿科杂志, 2020, 22(10):1047-1055.

21、唐军.早产儿喂养不耐受:一个重要的临床问题[J]. 中华围产医学杂志, 2020,23(3) :177-181.

1、王开明. 不同喂养方式对极低出生体重儿胃肠道并发症的影响[D]. 南昌大学医学部,2023.

2、黄丹,蓝国海,刘祥晖,等.振幅整合脑电图联合头颅磁共振预测早产儿矫正12月龄时神经发育的价值[J].广州医药,2024,55(05):513-518.

3、王琦,陈绿帆,龙小红,等.早产儿经胃管喂养后采用空气冲管的应用评价[J].广州医药,2024,55(09):1038-1042.